
CASI Pharmaceuticals, Inc. – NASDAQ:CASI
CASI Pharmaceuticals stock price today
CASI Pharmaceuticals stock price monthly change
CASI Pharmaceuticals stock price quarterly change
CASI Pharmaceuticals stock price yearly change
CASI Pharmaceuticals key metrics
Market Cap | 34.30M |
Enterprise value | 15.91M |
P/E | -1.31 |
EV/Sales | 0.42 |
EV/EBITDA | -0.66 |
Price/Sales | 1.02 |
Price/Book | 0.61 |
PEG ratio | -0.05 |
EPS | -2.23 |
Revenue | 28.15M |
EBITDA | -24.51M |
Income | -29.86M |
Revenue Q/Q | -59.15% |
Revenue Y/Y | -33.57% |
Profit margin | -73.17% |
Oper. margin | -88.53% |
Gross margin | 58.51% |
EBIT margin | -88.53% |
EBITDA margin | -87.05% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCASI Pharmaceuticals stock price history
CASI Pharmaceuticals stock forecast
CASI Pharmaceuticals financial statements
Jun 2023 | 9.82M | -10.23M | -104.27% |
---|---|---|---|
Sep 2023 | 8.83M | -4.63M | -52.44% |
Dec 2023 | 6.09M | -5.46M | -89.66% |
Mar 2024 | 3.40M | -9.52M | -279.5% |
Dec 2023 | 6.09M | -5.46M | -89.66% |
---|---|---|---|
Mar 2024 | 3.40M | -9.52M | -279.5% |
Sep 2025 | 12.5M | -6.82M | -54.6% |
Dec 2025 | 14.5M | -6.28M | -43.38% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 77874000 | 24.03M | 30.86% |
---|---|---|---|
Sep 2023 | 74228000 | 23.79M | 32.06% |
Dec 2023 | 75268000 | 51.10M | 67.89% |
Mar 2024 | 58011000 | 42.54M | 73.34% |
Jun 2023 | 0 | 0 | 0 |
---|---|---|---|
Sep 2023 | 0 | 0 | 0 |
Dec 2023 | 0 | 0 | 0 |
Mar 2024 | 0 | 0 | 0 |
CASI Pharmaceuticals alternative data
Aug 2023 | 224 |
---|---|
Sep 2023 | 224 |
Oct 2023 | 224 |
Nov 2023 | 224 |
Dec 2023 | 224 |
Jan 2024 | 224 |
Feb 2024 | 224 |
Mar 2024 | 224 |
Apr 2024 | 224 |
May 2024 | 176 |
Jun 2024 | 176 |
Jul 2024 | 176 |
CASI Pharmaceuticals other data
Period | Buy | Sel |
---|---|---|
Nov 2021 | 400000 | 0 |
Jun 2022 | 88154 | 0 |
Aug 2022 | 303723 | 0 |
Sep 2022 | 67794 | 0 |
Quarter | Transcript |
---|---|
Q2 2022 12 Aug 2022 | Q2 2022 Earnings Call Transcript |
Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
Q4 2021 28 Mar 2022 | Q4 2021 Earnings Call Transcript |
Q3 2021 12 Nov 2021 | Q3 2021 Earnings Call Transcript |
Week In Review: Sino Biopharm Subsidiary Enters $307 Million Agreement For Rights To NASH Candidate
Week In Review: Beijing BoomRay Closes $43 Million A Round For Novel Radionuclide Drugs
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
-
What's the price of CASI Pharmaceuticals stock today?
One share of CASI Pharmaceuticals stock can currently be purchased for approximately $2.17.
-
When is CASI Pharmaceuticals's next earnings date?
Unfortunately, CASI Pharmaceuticals's (CASI) next earnings date is currently unknown.
-
Does CASI Pharmaceuticals pay dividends?
No, CASI Pharmaceuticals does not pay dividends.
-
How much money does CASI Pharmaceuticals make?
CASI Pharmaceuticals has a market capitalization of 34.30M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21.41% to 33.88M US dollars.
-
What is CASI Pharmaceuticals's stock symbol?
CASI Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CASI".
-
What is CASI Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of CASI Pharmaceuticals?
Shares of CASI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are CASI Pharmaceuticals's key executives?
CASI Pharmaceuticals's management team includes the following people:
- Dr. Wei-Wu He Ph.D. Chairman & Chief Executive Officer(age: 60, pay: $819,490)
- Dr. Wei Zhang Ph.D. Pres & Principal Financial Officer(age: 66, pay: $715,770)
- Dr. Alexander A. Zukiwski M.D. Executive Vice President & Chief Medical Officer(age: 68, pay: $442,780)
-
How many employees does CASI Pharmaceuticals have?
As Jul 2024, CASI Pharmaceuticals employs 176 workers, which is 21% less then previous quarter.
-
When CASI Pharmaceuticals went public?
CASI Pharmaceuticals, Inc. is publicly traded company for more then 29 years since IPO on 12 Jun 1996.
-
What is CASI Pharmaceuticals's official website?
The official website for CASI Pharmaceuticals is casipharmaceuticals.com.
-
Where are CASI Pharmaceuticals's headquarters?
CASI Pharmaceuticals is headquartered at 9620 Medical Center Drive, Rockville, MD.
-
How can i contact CASI Pharmaceuticals?
CASI Pharmaceuticals's mailing address is 9620 Medical Center Drive, Rockville, MD and company can be reached via phone at +240 8642600.
CASI Pharmaceuticals company profile:

CASI Pharmaceuticals, Inc.
casipharmaceuticals.comNASDAQ
176
Biotechnology
Healthcare
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Rockville, MD 20850
CIK: 0000895051
ISIN: US14757U2087
CUSIP: 14757U208